DSDiana Pacheco Sousa

Diana Pacheco Sousa

*This is an algorithmically generated author record based on publicly available information.

Diana Pacheco Sousa has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • João Conde

    Comprehensive Health Research Centre (CHRC), NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, Lisbon, Portugal

    5 shared publications
  • Bárbara B. Mendes

    NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, Lisbon 1169-056, Portugal

    3 shared publications
  • Ana Teresa Pinto

    Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), 1099-023 Lisboa, Portugal

    2 shared publications
  • Branca Maria Cavaco

    Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) 1

    2 shared publications
  • João Conniot

    ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas (NMS|FCM), Universidade NOVA de Lisboa, Lisbon, Portugal

    2 shared publications
  • Marta Pojo

    Unidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal

    2 shared publications

Latest Publications

  • Open Access

    DNA/RNA Hybrid Hairpin Gold Nanobeacons Targeting miR-31 Reprogram Invasion in Lung Cancer and Remodel Tumor Histo-Architecture In Vivo

    by Diana P. Sousa, Jhenifer Oliveira, Catarina F. Martins, João Conde

    Readout-enabled delivery of anti-microRNA (miRNA) therapeutics remains a bottleneck for translating RNA nanomedicine against invasion and metastasis. We report ∼60 nm PEG-gold nanobeacons bearing a Cy3-labeled anti-miR-31-5p hairpin and establish a chemistry-to-phenotype pipeline spanning physicochemical control, cellular trafficking, functional phenotyping, miR-31 kinetics, transcriptomics, and histology-only in vivo analysis. The formulation exhibits invariant plasmonics, stepwise growth in hydrodynamic diameter with low dispersity, and moderated ζ-potential, confirming a stable, readout-enabled architecture. In lung cancer cells with high endogenous miR-31, nanobeacons are efficiently internalized, traffic predominantly to lysosomes, and selectively suppress 3D invasion at 10–20 nM while leaving 2D migration and viability unchanged. A low-miR-31 cell line shows minimal response, supporting target dependence. Time-course qRT-PCR reveals a delayed decrease in mature miR-31 (120–144 h) consistent with a two-phase mechanism: early functional sequestration by a minority cytosolic fraction followed by transcriptional down-tuning. Bulk RNA-seq at 72 h captures early remodeling of adhesion/ECM, integrin/TGF-β/WNT, and cytokine programs with directionality consistent with derepression of the miR-31 regulon. In xenografts locally exposed to nanobeacons, histology shows intratumoral Cy3-positive clusters, innate-immune-like infiltrates, focal reductions in Ki-67, fibrotic stroma, increased necrosis and inflammation, spatial evidence of local microenvironment remodeling without invoking tumor-size end points. Together, these results link precise materials design to a target-engaged, noncytotoxic anti-invasive outcome and define actionable levers, especially enhanced endosomal escape and pathway-level validation, to advance readout-enabled miRNA nanotherapeutics toward translation.

  • A large-scale machine learning analysis of inorganic nanoparticles in preclinical cancer research

    by Bárbara B. Mendes, Zilu Zhang, João Conniot, Diana P. Sousa, João M. J. M. Ravasco, Lauren A. Onweller, Andżelika Lorenc, Tiago Rodrigues, Daniel Reker, João Conde

    Owing to their distinct physical and chemical properties, inorganic nanoparticles (NPs) have shown promising results in preclinical cancer therapy, but designing and engineering them for effective therapeutic purposes remains a challenge. Although a comprehensive database of inorganic NP research is not currently available, it is crucial for developing effective cancer therapies. In this context, machine learning (ML) has emerged as a transformative tool, but its adaptation to nanomedicine is hindered by inexistent or small datasets. Here we assembled a large database of inorganic NPs, comprising experimental datasets from 745 preclinical studies in cancer nanomedicine. Using descriptive statistics and explainable ML models we mined this database to gain knowledge of inorganic NP design patterns and inform future NP research for cancer treatment. Our analyses suggest that NP shape and therapy type are prominent features in determining in vivo efficacy, measured as a percentage of tumour reduction. Moreover, our database provides a large-scale open-access resource for discriminative ML that the broader nanotechnology community can utilize. Our work blueprints data mining for translational cancer research and offers evidence for standardizing NP reporting to accelerate and de-risk inorganic NP-based drug delivery, which may help to improve patient outcomes in clinical settings.


  • Top Cited Papers
    Open Access

    A Fluorinated BODIPY-Based Zirconium Metal–Organic Framework for In Vivo Enhanced Photodynamic Therapy

    by Xu Chen, Bárbara B. Mendes, Yunhui Zhuang, João Conniot, Sergio Mercado Argandona, Francesca Melle, Diana P. Sousa, David Perl, Alexandru Chivu, Hirak K. Patra, et al.

    Photodynamic therapy (PDT), an emergent noninvasive cancer treatment, is largely dependent on the presence of efficient photosensitizers (PSs) and a sufficient oxygen supply. However, the therapeutic efficacy of PSs is greatly compromised by poor solubility, aggregation tendency, and oxygen depletion within solid tumors during PDT in hypoxic microenvironments. Despite the potential of PS-based metal-organic frameworks (MOFs), addressing hypoxia remains challenging. Boron dipyrromethene (BODIPY) chromophores, with excellent photostability, have exhibited great potential in PDT and bioimaging. However, their practical application suffers from limited chemical stability under harsh MOF synthesis conditions. Herein, we report the synthesis of the first example of a Zr-based MOF, namely, 69-L2, exclusively constructed from the BODIPY-derived ligands via a single-crystal to single-crystal post-synthetic exchange, where a direct solvothermal method is not applicable. To increase the PDT performance in hypoxia, we modify 69-L2 with fluorinated phosphate-functionalized methoxy poly(ethylene glycol). The resulting 69-L2@F is an oxygen carrier, enabling tumor oxygenation and simultaneously acting as a PS for reactive oxygen species (ROS) generation under LED irradiation. We demonstrate that 69-L2@F has an enhanced PDT effect in triple-negative breast cancer MDA-MB-231 cells under both normoxia and hypoxia. Following positive results, we evaluated the in vivo activity of 69-L2@F with a hydrogel, enabling local therapy in a triple-negative breast cancer mice model and achieving exceptional antitumor efficacy in only 2 days. We envision BODIPY-based Zr-MOFs to provide a solution for hypoxia relief and maximize efficacy during in vivo PDT, offering new insights into the design of promising MOF-based PSs for hypoxic tumors.


  • Open Access

    SPRY4 as a Potential Mediator of the Anti-Tumoral Role of Macrophages in Anaplastic Thyroid Cancer Cells

    by Ana Teresa Pinto, Marta Pojo, Ricardo Rodrigues, Diana Pacheco Sousa, Rune Matthiesen, Ana Sofia Carvalho, Hans C. Beck, Carolina Pires, Rodrigo Eduardo, Joana Simões Pereira, et al.

    Anaplastic thyroid carcinoma (ATC) is the most lethal subtype of thyroid cancer, with high invasive and metastatic potential, not responding to conventional treatments. Its aggressiveness may be influenced by macrophages, which are abundant cells in the tumor microenvironment. To investigate the role of macrophages in ATC aggressiveness, indirect co-cultures were established between ATC cell lines and THP-1-derived macrophages. Macrophages significantly increased both the migration and invasion of T235 cells (p < 0.01; p < 0.01), contrasting with a decrease in C3948 (p < 0.001; p < 0.05), with mild effects in T238 migration (p < 0.01) and C643 invasion (p < 0.05). Flow cytometry showed upregulation of CD80 (pro-inflammatory, anti-tumoral) and downregulation of CD163 (anti-inflammatory, pro-tumoral) in macrophages from co-culture with T235 (p < 0.05) and C3948 (p < 0.05), respectively. Accordingly, we found an upregulation of secreted pro-inflammatory mediators (e.g., GM-CSF, IL-1α; p < 0.05) in C3948–macrophage co-cultures. Proteomic analysis showed the upregulation of SPRY4, an inhibitor of the MAPK pathway, in C3948 cells from co-culture. SPRY4 silencing promoted cancer cell invasion, reverting the reduced invasion of C3948 caused by macrophages. Our findings support that macrophages play a role in ATC cell aggressiveness. SPRY4 is a possible modulator of macrophage–ATC cell communication, with a tumor suppressor role relevant for therapeutic purposes.


  • Open Access

    Gold Nanoconjugates for miRNA Modulation in Cancer Therapy: From miRNA Silencing to miRNA Mimics

    by Diana P. Sousa, João Conde

    Cancer is a major healthcare burden and cause of death worldwide, with an estimated 19.3 million new cancer cases and 10 million cancer deaths globally only in 2020. While several anticancer therapeutics are available to date, many of these still show low treatment efficacy and high off-target effects and adverse reactions. This prompts a serious need to develop novel therapies that can decrease the side effects and increase treatment efficacy. MicroRNAs (miRNAs) can have a role in tumor development and progression, making them important targets for the improvement of anticancer therapies. In this context, gold nanoparticles have been widely studied for different clinical applications due to their biocompatibility and possibility of customization, and gold nanoconjugates targeting miRNAs are being developed for cancer diagnosis and treatment. Here we summarize the research developed so far and how it can contribute to cancer treatment, discuss how it can be improved, and present the current challenges and future perspectives on their design and application.


  • Nanomedicine-based strategies to target and modulate the tumor microenvironment

    by Bárbara B. Mendes, Diana P. Sousa, João Conniot, João Conde


  • Nobiletin Alone or in Combination with Cisplatin Decreases the Viability of Anaplastic Thyroid Cancer Cell Lines

    by Diana P. Sousa, Marta Pojo, Ana T. Pinto, Valeriano Leite, Ana Teresa Serra, Branca M. Cavaco

    Aim: Anaplastic thyroid cancer (ATC) is the most aggressive subtype of thyroid cancer, presenting high mortality. Currently, no curative treatments exist and new therapeutic strategies are required. Although nutraceuticals were reported to have anticancer properties, few studies exist on ATC. This study aimed to investigate the anticancer effects of nutraceuticals in ATC cell lines (T235, T238) in comparison with normal thyroid cells (PCCL3). Methods: The IC50 values of isothiocyanates (ITCs: sulforaphane, SFN; phenethyl isothiocyanate, PEITC) and polymethoxylated flavones (PMFs: nobiletin; orange peel extract, OPE) were determined. ITCs decreased ATC metabolic viability more efficiently than PMFs. The effects of PEITC and nobiletin on viability and cell cycle, alone or in combination with conventional drugs, were evaluated. Results: PEITC did not affect viability of normal thyroid and ATC cells, while nobiletin decreased viability in a dose-dependent manner in all cell lines, although cell cycle was not arrested. At 100 μM, nobiletin reduced ATC cell viability as efficiently as conventional drugs, such as cisplatin, while being less toxic to normal thyroid cells. When conjugated with 1 μM cisplatin, the combination decreased viability of T235 cells more efficiently than each compound alone. Conclusion: These results suggest nobiletin as a potential anticancer agent that warrants further investigation in ATC.


  • Open Access

    Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids

    by Liliana R. Loureiro, Diana P. Sousa, Dylan Ferreira, Wengang Chai, Luís Lima, Carina Pereira, Carla B. Lopes, Viviana G. Correia, Lisete M. Silva, Chunxia Li, et al.

    Incomplete O-glycosylation is a feature associated with malignancy resulting in the expression of truncated glycans such as the sialyl-Tn (STn) antigen. Despite all the progress in the development of potential anti-cancer antibodies, their application is frequently hindered by low specificities and cross-reactivity. In this study, a novel anti-STn monoclonal antibody named L2A5 was developed by hybridoma technology. Flow cytometry analysis showed that L2A5 specifically binds to sialylated structures on the cell surface of STn-expressing breast and bladder cancer cell lines. Moreover, immunoblotting assays demonstrated reactivity to tumour-associated O-glycosylated proteins, such as MUC1. Tumour recognition was further observed using immunohistochemistry assays, which demonstrated a high sensitivity and specificity of L2A5 mAb towards cancer tissue, using bladder and colorectal cancer tissues. L2A5 staining was exclusively tumoural, with a remarkable reactivity in invasive and metastasis sites, not detectable by other anti-STn mAbs. Additionally, it stained 20% of cases of triple-negative breast cancers, suggesting application in diseases with unmet clinical needs. Finally, the fine specificity was assessed using glycan microarrays, demonstrating a highly specific binding of L2A5 to core STn antigens and additional ability to bind 2–6-linked sialyl core-1 probes. In conclusion, this study describes a novel anti-STn antibody with a unique binding specificity that can be applied for cancer diagnostic and future development of new antibody-based therapeutic applications.